Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

regulatory

- PMLiVE

A catalyst for change

China’s plan to boost innovation and improve drug accessibility

Risky business for pharma

China, Russia and Brazil are expected to provide the most issues

Transforming access in rare diseases

A quiet revolution is underway that could transform access to medicines in rare diseases, according to Duchenne UK, the charity at the heart of a new project to streamline evidence-gathering...

- PMLiVE

Focus on the fundamentals

Effectively working in an increasingly regulated environment

- PMLiVE

Effective strategic planning

The advantages of being nimble when responding to challenges

- PMLiVE

European CTR implementation advances ethical assessment of clinical trials

Assessment process is being integrated into national laws

- PMLiVE

Europe vs the US: New drug product approvals

As US approvals rates in the US drop,  the EU is not currently showing a similar trend

- PMLiVE

21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare

The 21st Century Cures Act has transformed the US drug development landscape. David Cooney explores the implications of the Act for pharmaceutical companies and reveals how it can be leveraged.

Blue Latitude Health

17 In Search of the Invisible Army

The caregivers' story

Havas Lynx

- PMLiVE

Stress testing for the perfect compliance storm

...as governments and regulators impose new legislation and strengthen their compliance regimes

- PMLiVE

Promoting off-label use: where to draw the line?

Looking at the trend among EU member states to actively promote the off-label use of medicines

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links